Xeris Biopharma Holdings (XERS) Non Operating Income (2020 - 2026)

Xeris Biopharma Holdings has reported Non Operating Income for 7 years, with the latest figure at -$5.7 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income rose 7.31% year-over-year to -$5.7 million; the trailing twelve-month figure through Mar 2026 stood at -$23.9 million (up 5.03% YoY), and the FY2025 full-year result was -$24.3 million, down 3.77% from the prior year.
• Non Operating Income for Q1 2026 stood at -$5.7 million, roughly flat from -$5.7 million in the prior quarter.
• The five-year high for Non Operating Income was $1.9 million in Q4 2022, with the low at -$7.6 million in Q3 2023.
• Historically, Non Operating Income has averaged -$5.1 million across 5 years, with a median of -$5.7 million in 2025.
• The largest YoY upside for Non Operating Income was 175.51% in 2022 against a maximum downside of 340.28% in 2022.
• Xeris Biopharma Holdings' Non Operating Income stood at $1.9 million in 2022, then tumbled by 299.0% to -$3.8 million in 2023, then plunged by 79.45% to -$6.8 million in 2024, then rose by 16.2% to -$5.7 million in 2025, then increased by 0.18% to -$5.7 million in 2026.
• The last three Non Operating Income figures came in at -$5.7 million (Q1 2026), -$5.7 million (Q4 2025), and -$6.1 million (Q3 2025), per Business Quant data.